Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.

Ament, Michael; Day, Kathleen; Stauffer, Virginia L; Skljarevski, Vladimir; Rettiganti, Mallikarjuna; Pearlman, Eric; Aurora, Sheena K

Ament, Michael; Day, Kathleen; Stauffer, Virginia L; Skljarevski, Vladimir; Rettiganti, Mallikarjuna; Pearlman, Eric; Aurora, Sheena K.

Afiliación

Ament M; Ament Headache Center, Denver, CO, 80206, USA.
Day K; Eli Lilly and Company, Indianapolis, IN, 46285, USA. day_kathleen_ann@lilly.com.
Stauffer VL; Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Skljarevski V; Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Rettiganti M; Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Pearlman E; Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Aurora SK; Eli Lilly and Company, Indianapolis, IN, 46285, USA.

J Headache Pain ; 22(1): 100, 2021 Aug 26.

Article en En | MEDLINE | ID: mdl-34445967

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: J Headache Pain Asunto de la revista: MEDICINA INTERNA / NEUROLOGIA / PSICOFISIOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google